No Data
No Data
Express News | Portage Biotech Shares Are Trading Higher After the Company Announced the Spinoff of Its Subsidiary Cyncado Therapeutics
Portage Biotech Re-Launches Subsidiary as Cyncado Therapeutics With New CEO
Portage: Cyncado to Focus on Advancing Clinical Development of A2a and A2b Receptor Antagonists to Achieve Proof-of-Concept Data for Its Therapeutics >PRTG
Portage Biotech: Peter Molloy Appointed to Lead New Company >PRTG
Portage Biotech: Adenosine Subsidiary to Become an Independently Managed Company >PRTG
Top Premarket Decliners